BACKGROUND

Achalasia-addisonianism-alacrima syndrome (MIM: 231550), frequently referred to as Allgrove syndrome or Triple A syndrome, is a multisystem disorder described by Allgrove et al. (1978), at which time the genetic etiology was unknown (Allgrove et al., 1978). Allgrove syndrome is typically characterized by the presence of three classical features—esophageal achalasia, alacrima, and adrenal insufficiency due to adrenocorticotropic hormone (ACTH) insensitivity (Allgrove et al., 1978; Handschug et al., 2001; Houlden et al., 2002). Allgrove syndrome has a wide and variable phenotypic spectrum, with patients presenting additional features including autonomic dysfunction, short stature, microcephaly,
optic atrophy, dermatologic abnormalities, and muscle weakness and atrophy (Handschu et al., 2001; Houlden et al., 2002; Kimber et al., 2003; Milenkovic et al., 2010). Typically alacrima present in infancy, while achalasia and adrenal insufficiency may appear in childhood or adulthood (Gaiani et al., 2020; Kimber et al., 2003; Milenkovic et al., 2010). All three classical features are observed in approximately two thirds of cases, with the remainder presenting only two classical symptoms (Roucher-Boulez et al., 2018).

Pathogenic homozygous or compound heterozygous variants in the gene encoding aladin (AAAS) have been shown to cause Allgrove Syndrome (Handschu et al., 2001; Tullio-Pelet et al., 2000). Most pathogenic variants described are frameshift, nonsense, or splice site variants that result in a loss of gene function (Handschu et al., 2001; Houlden et al., 2002; Kurnaz et al., 2018; Milenkovic et al., 2010; Roucher-Boulez et al., 2018; Sandrini et al., 2001; Singh et al., 2018; Tullio-Pelet et al., 2000). Less commonly missense variants have been associated with Allgrove Syndrome (Houlden et al., 2002; Krumbholz et al., 2006; Roucher-Boulez et al., 2018). There is no correlation between variant type or location and clinical phenotype, and individuals with the same variants may exhibit phenotypic variability (Goizet et al., 2002; Sandrini et al., 2001).

AAAS encodes Aladin WD Repeat Nucleoporin (aladin), which is a member of the WD-repeat family of proteins. The aladin protein is highly conserved in eukaryotes and is a nucleoporin involved in the formation of the nuclear pore complex (NPC). It is thought to be involved in nucleocytoplasmic transport. The C-terminal protein domain is necessary but not sufficient for localization to the NPC (Cronshaw & Matunis, 2003). The WD-repeats have also been shown to be involved in NPC localization (Cronshaw & Matunis, 2003; Krumbholz et al., 2006). Pathogenic variants in AAAS reduce localization of aladin to the NPC, and increase aladin within the cytoplasm (Cronshaw & Matunis, 2003; Krumbholz et al., 2006). This is mediated by loss of function variants as well as missense variants within the WD-repeats (Cronshaw & Matunis, 2003; Krumbholz et al., 2006).

2  |  MATERIALS AND METHODS

2.1  |  Ethical compliance

The proband and family members provided written consent following Mayo Clinic Institutional Review Board approval.

2.2  |  Whole-exome sequencing analysis

Genomic DNA from the proband, parents, and affected sibling was extracted from blood. The DNA was enriched for the complete coding regions and splice site junctions for most genes of the human genome using a proprietary capture system developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNv). The enriched targets were simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads were assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. Data were filtered and analyzed to identify sequence variants. Reported clinically significant variants were confirmed by an appropriate orthogonal method in the proband and family members.

2.3  |  Generation of GFP-tagged construct, immunocytochemistry, and quantification

Human AAAS (NM_015665.5) in pcDNA3.1(+-)-N-eGFP constructs were purchased from Genscript to contain the wild-type sequence, or with variants c.809G>C p.(Arg270Pro), or c.500C>T p.(Ala167Val).

HeLa cells were plated at 5 × 10⁵ cells per well on poly-D-lysine (Sigma, Cat No. P6407)-coated glass coverslips and incubated at 37°C overnight. The following day, the cells were transfected with the GFP-tagged constructs using Lipofectamine 3000 reagent (Invitrogen, Cat No. L3000008). After 48 hours, cells were fixed in 4% formaldehyde and permeabilized with 0.2% Triton X-100. Cells were stained with nucleoporin p62 (Nup62) antibody diluted 1:500 for 1 hour at room temp. Slides were then incubated with goat anti-mouse IgG Alexa Fluor 555 secondary antibody (Invitrogen, Cat No. A21424) diluted 1:500 for 1 hour at room temp. Slides were then mounted in Vectashield with DAPI (Vector Laboratories, Cat No. H-1500) and images were obtained using an LSM 980 with Airyscan 2 confocal microscope with a 63×/oil objective (ZEISS). Quantification was measured by obtaining the Mander’s co-localization coefficient of Nup62 with aladin protein for individual cells of each construct AAAS wild-type, p.A167V, and p.R270P (n = 42 cells, 48 cells, and 38 cells, respectively) using Lipofectamine 3000 reagent (Invitrogen, Cat No. A21424) diluted 1:500 for 1 hour at room temp. Slides were then mounted in Vectashield with DAPI (Vector Laboratories, Cat No. H-1500) and images were obtained using an LSM 980 with Airyscan 2 confocal microscope with a 63×/oil objective (ZEISS). Quantification was measured by obtaining the Mander’s co-localization coefficient of Nup62 with aladin protein for individual cells of each construct AAAS wild-type, p.A167V, and p.R270P (n = 42 cells, 48 cells, and 38 cells, respectively) using the Zen imaging software (ZEISS) and analyzed in GraphPad Prism using ANOVA to compare the variants to wild-type (*p < .05, **p < .01, ***p < .001, ****p < .0001).

3  |  RESULTS

3.1  |  Case presentation

The proband presented to the genetics clinic at age 29 to seek a diagnosis for a history of seizures, achalasia, optic
atrophy, muscle weakness, neuropathy, and autonomic dysfunction. The proband was born at 36 weeks gestation and required a brief NICU stay due to hypotonia and poor feeding. There were no additional complications, and initial milestones in infancy were normal. He had lifelong hypolacrimation with a recent abnormal Schirmer tear test. At 11 months of age he had his first seizure, with many thereafter. The seizures were initially thought to be febrile in nature, but later when it became clear that he had a true seizure disorder, he was diagnosed with epilepsy. He was treated with phenobarbital until age eight, at which time treatment was discontinued due to lack of seizure activity. He has not had seizures since. At age 11 he developed achalasia and dysphagia. MRI of his chest showed a dilated esophagus in keeping with the reported achalasia, which was corrected with a Heller myotomy. Around age 11 visual problems emerged, and he was diagnosed with optic atrophy. Distal muscle weakness started at age 18 and has progressed over time. Around age 24 the weak distal muscles were atrophying, and dysarthria began. He also developed a tingling sensation in his hands. The proband has a longstanding history of erectile dysfunction and the inability to ejaculate. From a GI standpoint he has a longstanding history of erectile dysfunction and the inability to ejaculate. We performed autonomic reflex screening at age 28 which showed a moderate autonomic neuropathy. Brain MRI showed a left frontal lobe developmental venous anomaly, which was assessed as incidental both in regard to his epilepsy and later his AAAS. His electromyography and nerve conduction studies at age 29 were abnormal and indicated a very chronic, slowly evolving, or static motor predominant neurogenic process. Currently, the proband continues to have GI discomfort, pain, and constipation. The intermittent tingling and numbness in his hands have increased in frequency. He has not developed any new medical problems since genetic testing was completed, and still does not have any identifiable endocrine abnormality.

3.2 | Family history

The proband’s parents did not present with any shared symptoms with the proband. He had three sisters, two of whom are healthy, and one who exhibits similar phenotypes to the proband, including alacrima, achalasia, and slurred speech (Figure 1). Overall, her presentation has been reported by family members to be milder than the proband.

3.3 | Genetic analysis and functional assessment of a AAAS VUS

A pathogenic variant, c.211delC, p.(His71Ilefs*23) in AAAS (NM_015665.5), was inherited from the proband’s unaffected father (Table 1). This variant had been previously observed in family with Allgrove syndrome (Houlden et al., 2002). A second AAAS variant, c.809G > C, p.(Arg270Pro), was inherited from the proband’s unaffected mother (Table 1). This alteration was classified as a variant of uncertain significance (VUS). The proband’s affected sister was also found to be compound heterozygous for these variants.
The maternally inherited VUS was not observed in large population cohorts (Lek et al., 2016), and in silico tools were conflicting in regards to its impact on protein structure and function. Conservation-based tool SIFT and a high CADD Phred Score (23.6) suggested that the variant is deleterious. In contrast, Polyphen2, MutationTaster, and PredictSNP2 suggested that the variant is tolerated. The altered arginine residue is conserved in chimps and orangutans, but not across other mammalian orthologues. This residue falls within exon 8 of 16 total AAAS exons, and in one of the WD-repeats. It is not predicted to impact splicing (Jaganathan et al., 2019).

To further understand the functional impact of this VUS, a GFP-tagged construct containing the p.(Arg-270Pro) variant was expressed in HeLa cells, and aladin protein localization was observed. In control cells aladin co-localizes with nucleoporin 62 (NUP62) at the nuclear pore (Figure 2). In positive control cells expressing a known pathogenic missense variant, p.(Ala167Val), and cells expressing the p.(Arg270Pro) variant, we observed a significant loss of co-localization with NUP62 and mis-localization of aladin to the cytoplasm (Figure 2). These data indicate that this variant results in aberrant localization of the aladin protein.

### TABLE 1 Genomic findings

| Gene | Transcript | HGVS cDNA | HGVS protein | Zygosity | Inheritance | ACMG classification |
|------|------------|-----------|--------------|----------|-------------|---------------------|
| AAAS | NM_015665.5 | c.211delC  | p.His71Ilefs*23 | Heterozygous | Paternal | Pathogenic |
| AAAS | NM_015665.5 | c.809G>C | p.Arg270Pro | Heterozygous | Maternal | VUS |

Abbreviations: ACMG, American College of Medical Genetics and Genomics; HGVS, Human genome variation society.

**FIGURE 2** Functional assessment of AAAS VUS. (a) HeLa cells with GFP-tagged wild-type or mutant aladin (green) and NUP62 (red) labeling the NPC. (b) Insert of the merged panel from 2A showing co-localization of aladin and NUP62 in wild-type cells (yellow) and significantly reduced co-localization in cells expressing the proband’s variant. (c) Quantification of co-localization of aladin and NUP62 in wild-type cells, cells expressing a pathogenic variant (positive control), and cells expressing the patient variant.
assessment of this variant using previously established methods (Krumbholz et al., 2006) with inclusion of positive and negative controls allows for the application of PS3 supporting criteria (Brnich et al., 2019; Richards et al., 2015), elevating this variant to likely pathogenic. While the affected sister harbors both of the AAAS variants, PP1 criteria is not able to be applied due to insufficient numbers of affected family members to test for segregation.

Interestingly, the proband does not exhibit the adrenal dysfunction classically seen in Triple A syndrome. He has had several instances of adrenocorticotropic hormone testing, each of which was normal (Supplemental Table S1). However, it is important to note that the proband is relatively young, and although unlikely, adrenal insufficiency could still present later in life. There have been rare reports of Triple A patients presenting with only alacrima and achalasia, and only two of the classical criteria are required for diagnoses (Gaiani et al., 2020; Rivera-Suazo et al., 2020). This highlights the importance of careful consideration of variants in AAAS in the absence of all three classical features and demonstrates the utility of research-based testing for the functional impact of VUSs. While the patient only exhibits two of the classical features, his expanded phenotype is consistent with additional features of Allgrove syndrome reported in the literature. Specifically, his autonomic dysfunction, optic atrophy, anejaculation, and amyotrophy are all consistent with previously reported cases. Review of the patients clinical, pathological, and genetic findings resulted in a diagnosis of Allgrove syndrome for the proband.

ACKNOWLEDGMENTS
This work was supported by the Mayo Clinic—Center for Individualized Medicine (CIM), Translational Omics Program. The authors would also like to thank the proband and their family for their participation in this study.

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
Erica L. Macke analyzed data and drafted the manuscript. Erica L. Macke, Christopher T. Schmitz, and Eric W. Klee contributed to data collection and analysis. Sarah K. Macklin-Mantia, Björn Oskarsson, and Klaas J. Wierenga carried out family recruitment and clinical analysis. Eric W. Klee and Klaas J. Wierenga supervised the work. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES
Allgrove, J., Clayden, G. S., Grant, D. B., & Macaulay, J. C. (1978). Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. The Lancet, 311(8077), 1284–1286. https://doi.org/10.1016/S0140-6736(78)91268-0
Brnich, S. E., Abou Tayoun, A. N., Couch, F. J., Cutting, G. R., Greenblatt, M. S., Heinen, C. D., Kanavy, D. M., Luo, X., McNulty, S. M., Starita, L. M., Tavitgian, S. V., Wright, M. W., Harrison, S. M., Biesecker, L. G., & Berg, J. S. (2019). Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Medicine, 12(1), 1–12. https://doi.org/10.1186/S13073-019-0690-2
Cronshaw, J., & Matunis, M. (2003). The nuclear pore complex protein ALADIN is mislocalized in triple a syndrome. Proceedings of the National Academy of Sciences of the United States of America, 100(10), 5823–5827. https://doi.org/10.1073/PNAS.1031047100
Gaiani, F., Gismondi, P., Minelli, R., Casadio, G., De’Angelis, N., Fornaroli, F., De’Angelis, G. L., & Manfredi, F. (2020). Case report of a familial triple: A syndrome and review of the literature. Medicine, 99(22), e20474. https://doi.org/10.1097/MD.0000000000020474
Goizet, C., Catargi, B., Tison, F., Tullio-Pelet, A., Hadj-Rabia, S., Pujol, F., Laguemy, A., Lyonnet, S., & Lacombe, D. (2002). Progressive bulbospinal amyotrophy in triple a syndrome with AAAS gene mutation. Neurology, 58(6), 962–965. https://doi.org/10.1212/WNL.58.6.962
Handschug, K., Sperling, S., Yoon, S., Hennig, S., Clark, A., & Huebner, A. (2001). Triple a syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Human Molecular Genetics, 10(3), 283–290. https://doi.org/10.1093/HMG/10.3.283
Houlden, H., Smith, S., De Carvalho, M., Blake, J., Mathias, C., Wood, N. W., & Reilly, M. M. (2002). Clinical and genetic characterization of families with triple a (Allgrove) syndrome. Brain, 125(12), 2681–2690. https://doi.org/10.1093/brain/awf270
Jaganathan, K., Kyriazopoulou Panagiotopoulou, S., McRae, J. F., Darbandi, S. F., Knowles, D., Li, Y. I., Kosmicki, J. A., Arbelaez, J., Cui, W., Schwartz, G. B., Chow, E. D., Kanterakis, E., Gao, H., Kia, A., Batzoglou, S., Sanders, S. J., & Farh, K. K.-H. (2019). Predicting splicing from primary sequence with deep learning. Cell, 176(3), 535–548.e24. https://doi.org/10.1016/J.CELL.2018.12.015
Kimber, J., McLean, B., Prevett, M., & Hammans, S. (2003). Allgrove or 4 “a” syndrome: An autosomal recessive syndrome causing multisystem neurological disease. Journal of Neurology, Neurosurgery, and Psychiatry, 74(5), 654–657. https://doi.org/10.1136/JNPP.74.5.654
Krumbholz, M., Koehler, K., & Huebner, A. (2006). Cellular localization of 17 natural mutant variants of ALADIN protein in triple
a syndrome - shedding light on an unexpected splice mutation. Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire, 84(2), 243–249. https://doi.org/10.1139/O05-198

Kurnaz, E., Duminuco, P., Aycan, Z., Savaş-Erdeve, S., Muratoğlu Şahin, N., Keskin, M., Bayramoğlu, E., Bonomi, M., & Çetinkaya, S. (2018). Clinical and genetic characterisation of a series of patients with triple a syndrome. European Journal of Pediatrics, 177(3), 363–369. https://doi.org/10.1007/S00431-017-3068-8

Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., Cummings, B. B., Tukiainen, T., Birnbaum, D. P., Kosmicki, J. A., Duncan, L. E., Estrada, K., Zhao, F., Zou, J., Pierce-Hoffman, E., Berghout, J., ... MacArthur, D. G. (2016). Analysis of protein-coding genetic variation in 60,706 humans. Nature, 536(7616), 285–291. https://doi.org/10.1038/nature19057

Milenkovic, T., Zdravkovic, D., Savic, N., Todorovic, S., Mitrovic, K., Koehler, K., & Huebner, A. (2010). Triple a syndrome: 32 years experience of a single Centre (1977-2008). European Journal of Pediatrics, 169(11), 1323–1328. https://doi.org/10.1007/s00431-010-1222-7

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., & Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–424. https://doi.org/10.1038/gim.2015.30

Rivera-Suazo, Y., Espriu-Ramirez, M. X., Trauernicht-Mendieta, S. A., & Rodríguez, L. (2020). Allgrove syndrome in a toddler: Alacrima and achalasia, with no adrenal insufficiency. Revista de Gastroenterología de Mexico, 86, 439–453. https://doi.org/10.1016/j.rjgmx.2020.09.003

Roucher-Boulez, F., De La Perriere, A. B., Jacquez, A., Chau, D., Guignat, L., Vial, C., Morel, Y., Nicolino, M., Raverot, G., & Pugeot, M. (2018). Triple-a syndrome: A wide spectrum of adrenal dysfunction. European Journal of Endocrinology, 178(3), 199–207. https://doi.org/10.1530/EJE-17-0642

Sandrini, F., Farmakidis, C., Kirschner, L. S., Wu, S.-M., Tullio-Pelet, A., Lyonnet, S., Metzger, D. L., Bourdony, C. J., Tiosano, D., Chan, W. Y., & Stratakis, C. A. (2001). Spectrum of mutations of the AAAS gene in Allgrove syndrome: Lack of mutations in six kindreds with isolated resistance to corticotropin. The Journal of Clinical Endocrinology & Metabolism, 86(11), 5433–5437. https://doi.org/10.1210/JCEM.86.11.8037

Singh, K., Puri, R., Bhai, P., Arya, A., Chawla, G., Saxena, R., & Verma, I. (2018). Clinical heterogeneity and molecular profile of triple a syndrome: A study of seven cases. Journal of Pediatric Endocrinology & Metabolism, 31(7), 799–807. https://doi.org/10.1515/JPEM-2018-0023

Smith, T., Gaitatzes, C., Saxena, K., & Neer, E. (1999). The WD repeat: A common architecture for diverse functions. Trends in Biochemical Sciences, 24(5), 181–185. https://doi.org/10.1016/S0968-0004(99)01368-0

Tullio-Pelet, A., Salomon, R., Hadj-Rabia, S., Mugnier, C., de Laet, M., Chauouachi, B., Bakiri, F., Brottier, P., Cattolico, L., Penet, C., Bégeot, M., Naville, D., Nicolino, M., Chaussain, J. L., Weissenbach, J., Munnich, A., & Lyonnet, S. (2000). Mutant WD-repeat protein in triple-a syndrome. Nature Genetics, 26(3), 332–335. https://doi.org/10.1038/81642

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Macke, E. L., Morales-Rosado, J. A., Macklin-Mantia, S. K., Schmitz, C. T., Oskarsson, B., Klee, E. W., & Wierenga, K. J. (2022). Functional validation of a novel AAAS variant in an atypical presentation of Allgrove syndrome. Molecular Genetics & Genomic Medicine, 10, e1966. https://doi.org/10.1002/mgg3.1966